How Much Did Epic Sciences Raise?
Funding & Key Investors

Epic Sciences, a developer of diagnostic tests for molecularly characterizing circulating tumor cells in the blood, has secured significant capital, with its total funding reaching $220.5M. The company recently announced a major strategic investment of $24M, underscoring its continued growth and market position in the precision diagnostics sector. This latest financing round follows a series of strategic capital infusions that have supported its development and expansion.

What is Epic Sciences?

Epic Sciences
Business ServicesResearch & DevelopmentHealthcare Services

Founded in 2008 and headquartered in San Diego, Epic Sciences Inc. is at the forefront of liquid biopsy technology. The company specializes in developing advanced diagnostic tests designed to molecularly characterize circulating tumor cells (CTCs) directly from a patient's blood. This innovative approach aims to provide critical insights into cancer biology, enabling more personalized and effective treatment strategies. By analyzing CTCs, Epic Sciences offers a non-invasive method for monitoring disease progression, assessing treatment response, and identifying potential therapeutic targets, thereby advancing the field of precision oncology.

How much funding has Epic Sciences raised?

Epic Sciences has raised a total of $220.5M across 9 funding rounds:

2014

Series C

$30M

2015

Debt

$15M

2017

Series D

$40M

2018

Other Financing Round

$52M

2020

Debt

$1M

2022

Series F

$43M

2023

Series G

$24M

Series C (2014): $30M supported by Domain Associates, Roche, Arcus Ventures, and Pfizer Venture Investments

Debt (2015): $15M featuring Silicon Valley Bank

Series D (2017): $40M backed by Genomic Health, Domain Associates, Hermed Capital, and Altos Capital Partners

Other Financing Round (2018): $52M with participation from Blue Ox Healthcare Partners

Debt (2020): $1M led by PPP

Series F (2022): $43M supported by Arsenal Capital Partners and Blue Ox Healthcare Partners

Series G (2023): $24M featuring Arsenal Capital Partners, Blue Ox Healthcare Partners, Labcorp, HC Domain Ventures, and Deerfield

Key Investors in Epic Sciences

Arsenal Capital Partners

Arsenal Capital Partners is a leading private equity firm specialized in investments in middle-market industrial growth and healthcare companies. Since its inception in 2000, the firm has distinguished itself through a "build-for-tomorrow" philosophy, focusing on high-growth, technology-, and innovation-rich businesses that are strategically important to their respective markets. Arsenals investment strategy is deeply rooted in sector expertise; the firm employs a team of nearly 100 professionals that includes seasoned industry executives, scientists, and technical experts. This allows the firm to partner effectively with management teams to execute multi-faceted growth strategies, often involving complex buy-and-build models.

Blue Ox Healthcare Partners

Blue Ox Healthcare Partners is a commercial-stage growth investor focused on precision health and individualized medicine. The company seeks to invest in growth-stage healthcare companies that offer technology-enabled innovations aimed at improving healthcare delivery, affordability, and precision health. By leveraging their expertise and industry relationships, Blue Ox guides these companies through the commercialization process to enhance patient outcomes and value. Their portfolio includes companies like Sera Prognostics, EPIC Sciences, and Gemelli Biotech, which are at the forefront of advancing personalized healthcare solutions.

Labcorp

Labcorp Holdings Inc. operates as a laboratory services company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates in two segments, Diagnostics Laboratories (Dx) and Biopharma Laboratory Services (BLS). The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C and vitamin D, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases; services related to anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing, occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations (MCOs), including health fairs, on-site and at-home testing, vaccinations, and health screenings. It serves pharmaceutical, biotechnology, medical device, and diagnostics companies; and MCOs, employer plans, other health insurance providers, governmental agencies, physicians and other healthcare providers, hospitals and health systems, employers, patients and consumers, contract research organizations, crop protection and chemical companies, academic institutions, independent clinical laboratories, and retailers.

What's next for Epic Sciences?

With its latest major strategic investment, Epic Sciences is poised to further accelerate its research and development initiatives and expand its commercial reach. The substantial capital infusion, particularly following its Series G round, indicates strong investor confidence in the company's technology and its potential to disrupt cancer diagnostics. This funding will likely be directed towards enhancing its diagnostic platforms, broadening its test offerings, and forging new partnerships within the healthcare ecosystem. The company's trajectory suggests a continued focus on innovation in liquid biopsy and a commitment to improving patient outcomes through advanced molecular characterization.

See full Epic Sciences company page
See More Financial Insights
No matching results.
Refine your search.

Additional financial insights in the Business Services industry

Business ServicesField Service Management
Business ServicesProject ManagementSoftware Testing
Advertising NetworksBusiness ServicesData Collection & Internet PortalsMedia & Internet
Business ServicesChambers of Commerce

Frequently Asked Questions Regarding Epic Sciences Financial Insights

What are the most recent funding rounds that Epic Sciences has completed, and what were the funding rounds?
Epic Sciences has recently completed 3 funding rounds: Series G on Apr 14, 2023, Series F on Jun 1, 2022, Debt on Apr 14, 2020.
What is the total amount of funding Epic Sciences has raised to date?
Epic Sciences has raised a total of $220.5M in funding to date.
How many funding rounds has Epic Sciences completed?
Epic Sciences has completed 3 funding rounds.
How much funding did Epic Sciences raise in its most recent funding round?
Epic Sciences raised $24M in its most recent funding round.
Who are the lead investors in Epic Sciences's latest funding round?
The lead investor in Epic Sciences's latest funding round was Arsenal Capital Partners. To access investor data and explore similar companies, sign up for ZoomInfo.
Which was the largest funding round in Epic Sciences's history?
The largest funding round in Epic Sciences's history was $52M.
See more information about Epic Sciences